Hec1 (highly expressed in cancer 1) or Nek2 (NIMA-related kinase 2) is often overexpressed in cancers with poor prognosis. Both are critical mitotic regulators, and phosphorylation of Hec1 S165 by Nek2 is required for proper chromosome segregation. Therefore, inactivation of Hec1 and Nek2 by targeting their interaction with small molecules represents an ideal strategy for tackling these types of cancers. Here we showed that new derivatives of INH (inhibitor for Nek2 and Hec1 binding) bind to Hec1 at amino acids 394-408 on W395, L399 and K400 residues, effectively blocking Hec1 phosphorylation on S165 by Nek2, and killing cancer cells at the nanomolar range. Mechanistically, the D-box (destruction-box) region of Nek2 specifically binds to Hec1 at amino acids 408-422, immediately adjacent to the INH binding motif. Subsequent binding of Nek2 to INH-bound Hec1 triggered proteasomemediated Nek2 degradation, whereas the Hec1 binding defective Nek2 mutant, Nek2 R361L, resisted INH-induced Nek2 degradation. This finding unveils a novel drug-action mechanism where the binding of INHs to Hec1 forms a virtual death-trap to trigger Nek2 degradation and eventually cell death. Furthermore, analysis of the gene expression profiles of breast cancer patient samples revealed that co-elevated expressions of Hec1 and Nek2 correlated with the shortest survival. Treatment of mice with this kind of tumor with INHs significantly suppressed tumor growth without obvious toxicity. Taken together, the new INH derivatives are suitable for translation into clinical application.
INTRODUCTION
Mitosis is a highly intricate process that depends on the precise coordination of microtubules, kinesins and various kinases. Together, these molecules regulate proper spindle formation and faithful chromosome segregation in actively proliferating cells and are often considered promising anticancer therapeutic targets. [1] [2] [3] [4] Microtubule targeting agents, like taxanes and Vinca alkaloids, are commonly used in wide range of cancers by inducing cell death through poisoning the spindle apparatus and inhibiting mitotic progression. 5, 6 However, as microtubules are also a key component of neurons and rapidly cycling bone marrow cells, these spindle poisons inevitably elicit a plethora of severe pathological side effects that include: peripheral neurotoxicity, neuropathy, and myelosuppression. 5, 7 Therefore, there is a strong interest in developing chemical compounds that selectively inhibit mitotic kinesins (for example, 5/KSP and CENP-E) or mitotic kinases (for example, Aurora A and B) instead of microtubules. Currently, there are over 40 different anti-mitotic inhibitors in various stages of preclinical and clinical trials, 4, [8] [9] [10] which indicate that targeting mitotic apparatus is a useful strategy for treating cancer.
Hec1 (highly expressed in cancer 1) was originally identified as a Rb-interacting protein 11 and later found to be an essential member of Ndc80 complex along with Nuf2, Spc24 and Spc25. 12, 13 An early study using a neutralizing antibody to inactivate Hec1 indicated that Hec1 is critical for chromosome segregation. 11 Subsequent investigations using siRNA to deplete Hec1 further supported the idea that Hec1 has an important role in mitotic spindle checkpoint control. [14] [15] [16] [17] Overall, Hec1 acts as a mitotic regulator to modulate several mitotic processes, including chromosome condensation, migration and spindle assembly checkpoint signaling. 1, 11, 14, 17, 18 Hec1 overexpression has been observed in a variety of human cancers and is associated with adverse clinical outcomes in primary breast cancers. 11, 19, 20 In fact, overexpression of Hec1 in a mouse model resulted in spindle checkpoint hyperactivation and tumor formation. 21 On the other hand, depletion of Hec1 by virusmediated RNAi effectively retarded tumor growth in mouse models. 22, 23 Taken together, these results suggested that Hec1 is an important therapeutic target for developing novel anticancer regimen.
As phosphorylation of Hec1 S165 by Nek2 (NIMA-related kinase 2), a mitotic regulator, is critical for Hec1 function in modulating chromosome segregation, 17, 24 the interaction between Hec1 and Nek2 during mitosis represents an ideal target for developing inhibitors that specifically disrupt this interaction. We have previously identified compounds that block the Hec1/Nek2 interaction. 25 In this communication, we showed that the new leading compound INH154 (inhibitor for Nek2 and Hec1 binding 154) is highly potent in treating breast tumors with co-elevated expression of Hec1 and Nek2. We also demonstrated mechanistically that the binding of INHs to Hec1 forms a virtual death-trap to trigger Nek2 degradation and eventually cell death.
RESULTS

Generation of new small molecules as potent Hec1 inhibitor
In previous studies, we identified a small molecule INH1, which directly binds to Hec1 and inhibits cancer growth with an IC 50 within the 15 μM range. 25 To improve the drug efficacy, we first built a molecular model of Hec1 coiled-coil region by homology modeling based on the crystal structure of the coiled-coil protein Tropomyosin and then docked INH1 on this structure (Figure 1a and Supplementary Figure S1 ). It was noted that INH1 preferentially interacts with the first coiled-coil region of Hec1, and the thiazole moiety of INH1 showed a prominent stacking interaction with the indole moiety of Hec1 W395, which may significantly contribute to the binding with Hec1. Based on this docking model, an additional contact site consisting mainly of Hec1 residues, N396, L399, K400 and R403 was revealed (indicated by an arrow in Figure 1a ). To explore the potential chemical substituents that can geometrically occupy this new site, we designed a structurally focused chemical library and prepared these compounds following a diversity-oriented synthetic scheme. 26 Using this library, we identified INH41 as the lead compound of the second-generation INH, which had IC 50 in sub-μM range ( Table 1) . Third generation of INH derivatives were generated based on INH41. Among these compounds, INH154 was the most potent inhibitor of tumor cell growth ( Table 1 ). The IC 50 values of INH154 in HeLa and MDA-MB-468 cancer cells were 0.20 μM and 0.12 μM, respectively. In addition, both INH41 and INH154 suppressed the growth of leukemia, osteosarcoma and glioblastoma cells but had no significant growth inhibitory effects on non-tumorigenic fibroblast HS27 and mammary epithelial cell MCF10A (Figure 1b 30 we performed flow cytometry with Annexin-V/propidium iodide staining. 31 The percentages of apoptotic and necrotic cells were higher in the INH41-or INH154-treated cells (17.4%, 9.5% and 67.6%, 14.7%; respectively), compared with 1.8, 0.4% in DMSOtreated cells and 1.9, 1.1% in INH22-treated cells (Figure 2e ). Together, these results suggested that INH41 and INH154 cause mitotic catastrophe leading to cell death.
Determining the INH-binding specificity on Hec1
To determine the region of Hec1 that mediates the binding to INH 41 and INH154, we created a series of deletion mutants in the Hec1 coiled-coil 1 region 32 and performed pull-down assays using biotin-conjugated INHs (Figures 3a and b ). As shown in Figure 3b , biotin-conjugated INH41 was able to pull down all Hec1 deletion mutants except ΔL394-I408, suggesting that INH41 may directly bind to L394-I408 of Hec1. In contrast, biotin-conjugated negative compound INH22 failed to pull down even wild-type (WT) Hec1. Furthermore, neither Nek2 nor the binding partner of Hec1, Nuf2, was pulled down with INH41 ( Figure 3b ), indicating that INH preferentially bound to Hec1 instead of Nek2 or Nuf2. Based on molecular docking, it was noted that INH41 and INH154 formed prominent contact points with Hec1 W395, L399 and K400 (Figure 3c ). To validate the importance of these residues in determining INH-Hec1 interaction specificity, we conducted a biotin INH pull-down assay in cells expressing Hec1 W395A or W395A/L399A/K400A (WLK/AAA) mutants. As shown in Figure 3d , neither biotin-INH41 nor biotin-INH154 were able to bind either mutants or Nek2 (Figure 3d ), indicating that Hec1 W395 is essential for interacting with INHs.
As both mutants failed to bind INHs, one would expect that the cells expressing these mutants should acquire resistance to INH treatment. To test this possibility, we established MDA-MB-468 cells stably expressing Hec1 WT, W395A or WLK/AAA ( Figure 3e ) and then treated them with INHs. As shown in Figure 3f , cells expressing either Hec1 W395A or WLK/AAA showed significantly elevated IC 50 values for INH41 and INH154. Interestingly, expression of Hec1 triple mutant WLK/AAA resulted in more severe loss of growth inhibitory effect. To exclude the possibility that drug resistance was caused by inactive Hec1 functions, we measured the mitotic index in the cells overexpressing Hec1 WT, W395A or WLK/AAA. Both Hec1 W395A and WLK/AAA had no effect on mitotic index compared with Hec1 WT, even when endogenous Hec1 was depleted. This suggests that both Hec1 mutants can maintain, at least in part, normal Hec1 function in mitosis without obvious dominant-negative effect (Supplementary Figure S2 ). Taken together, these findings demonstrated that INH-Hec1 binding specificity is primarily mediated by W395, and L399 and K400 also contribute to the interaction.
INHs promote Nek2 degradation and inhibit Hec1 phosphorylation on S165
To delineate the cellular consequences upon INH treatment, we first examined Hec1 and Nek2 protein levels in INH41-or INH154treated cells. In a time course study, Nek2 level was remarkably reduced by >95% after 18 h of treatment with 1 μM INH41 or INH154, whereas little change was observed in Hec1 expression ( Figure 4a ), consistent with our previous finding. 25 Figure S5 ). As Nek2 is degraded through the proteasome pathway at prometaphase, 33 we then co-treated cells with INHs and the proteasome inhibitor MG132 and found MG132 treatment prevented the INH-induced degradation of Nek2 (Figures 4b and c ). However, INH treatment did not affect the stability of other mitotic molecules, including cyclin B and two mitotic kinases, Aurora A and PLK1 (Figure 4d and Supplementary Figure S3 ).
As phosphorylation of Hec1 S165 is Nek2 dependent and has been reported to have an important role in Hec1 function, 17, 24 it is likely that INH treatment would also abolish Hec1 S165 phosphorylation. As predicted, the phosphorylated Hec1 levels (pS165 Hec1) were notably reduced in a time-dependent fashion upon treating cells with 1 μM INH41 or INH154 for 4-24 h (Figure 4e ). In addition, immunostaining using the same phosphor-specific antibody showed a dramatic diminution in Hec1 phosphorylation signal at kinetochores after INH treatment compared with DMSO-treated cells relative to control antibody against ACA (anti-cardiolipin antibody; red) at kinetochores (Figures 4f and g) . Collectively, these data suggested that INH treatment inhibits Hec1 S165 phosphorylation by promoting proteasome-mediated Nek2 degradation. Binding of INHs to Hec1 forms a virtual death-trap to trigger Hec1-bound Nek2 degradation Next, we sought to explore how Nek2 degradation is triggered upon INH treatment. As both Hec1 W395A and WLK/AAA mutants exhibited resistance to INHs, it is likely that INH treatment may not induce Nek2 degradation in cells expressing these mutants. To test this possibility, we first performed a co-immunoprecipitation experiment using cells expressing Hec1 WT, W395A or WLK/AAA and showed that both Hec1 mutants retained Nek2 interaction and Hec1 S165 phosphorylation ( Figure 5a ). Noticeably, upon INH treatment, cells expressing either Hec1 W395A or WLK/AAA mutant failed to induce Nek2 degradation (Figure 5b and Supplementary Figure S6 ). These data suggested that Nek2 degradation induced by INH is dependent on INH binding to Hec1.
Next, we used the same Hec1 deletion mutants from Figure 2b to identify which region of Hec1 mediates the binding for Nek2. As shown in Figure 5c , the co-immunoprecipitation experiment demonstrated that region 3 (I408-L422) in Hec1 is the major interacting domain for Nek2 while region 2 (L394-I408) also contributed to the binding, albeit to a lesser extent. To examine whether Hec1-Nek2 interaction is required for INH-induced Nek2 degradation, we analyzed the change of Nek2 level after INH treatment with depletion of endogenous Hec1 and expression of siRNA-resistant Hec1 Δ3 mutant (ΔI408-L422). As shown in Figure 5d , Nek2 was not susceptible to INH-induced degradation when expressing Hec1 Δ3 mutant, suggesting that direct interaction between Hec1 and Nek2 is required for Nek2 degradation upon INH treatment.
To further verify the importance of Hec1-Nek2 interaction on INH-induced Nek2 degradation, we needed a Nek2 mutant that failed to bind to Hec1. Hot-spot analysis of protein-protein interaction implicated that the residues within the D-box (destruction-box) region of Nek2 may serve as a primary contact site for Hec1 binding (Supplementary Figure S7 and Supplementary Table S1 ). To test this possibility, we generated a D-box deletion mutant of Nek2A and performed co-immunoprecipitation experiment. As shown in Figure 5e , the Nek2A D-box deletion mutant failed to bind to Hec1, whereas Nek2A WT was able to coimmunopreciptiate with Hec1. To further pinpoint which residue within the Nek2A D-box region was critical for binding to Hec1, we performed optimal docking area analysis and found that Nek2A R361 appeared to be the best candidate according to the optimal docking area value ( Supplementary Table S1 ). We then generated a Nek2A mutant R361L and showed that it failed to bind to Hec1 by co-immunoprecipitation assay (Figure 5f ). Consistently, similar to Hec1 Δ3 mutant, Nek2A R361L was more resistant to INH154-induced degradation than WT Nek2A in a dose-and time-dependent manner (Figures 5g-j) . These results suggested that binding of Nek2 to Hec1 is a prerequisite for INH-induced Nek2 degradation.
Based on the above data, we proposed a potential mechanism to explain this observation. As described in Figures 5k and l, first, Nek2 normally binds to Hec1 and phosphorylates Hec1 on S165 at M phase in cells (Figure 5k ). Second, as the binding site of INHs to Hec1 is adjacent to Nek2 binding hot-spot site, it is likely that INH-bound Hec1 alters Hec1-bound Nek2 conformation, leading to proteasome-mediated Nek2 degradation and reduction of Hec1 S165 phosphorylation (Figure 5l) . Although the precise conformational change of this transient state of Nek2 remains to be established, the explanation described herein represents the most logical deductions.
Co-elevated expressions of Hec1 and Nek2 are associated with the poorest survival in breast cancer patients and INHs effectively ablate this kind of tumor progression in a xenograft model It was reported that upregulation of Hec1 or Nek2 in breast cancer correlated with tumor initiation and progression. 20, [34] [35] [36] To investigate whether this upregulation is associated with patient prognosis, we analyzed the gene expression profiles of patient samples from publicly available microarray databases ( Supplementary Table S2 ). The data set was assembled using R/Bioconductor 37 containing 2851 clinically annotated samples after outlier and duplicate sample removal. Our analysis showed that the Pearson correlation coefficient between Hec1 and Nek2 expression levels is 0.67 (Po 0.001) among the 2851 samples, suggesting that Hec1 and Nek2 expression levels are highly associated (Figure 6a ). Using a Kaplan-Meier Cox model, we analyzed the 10-year censored distant metastasis-free survival (n = 2435) and relapse-ree survival (n = 1056) probabilities of samples with Hec1 and Nek2 expression levels dichotomized at their respective median values. We found that patients with high levels of both Hec1 and Nek2 have the worst survival probability in both distant metastasis-free survival and relapse-free survival (Figures 6b and c) . These results conform the concept that targeting both Hec1 and Nek2 by INH offers a useful strategy in treating human breast cancer.
To further address this possibility, we used a serial of human breast cell lines to perform western blotting analysis and INH sensitivity assay. As shown in Supplementary Figure S8 , Hec1 and Nek2 expressed higher levels in malignant breast cancer cells than in benign breast cancer MCF7 cells or non-tumorigenic mammary epithelial MCF10A cells. As expected, the cell lines with high expression levels of Hec1 and Nek2 were more sensitized to INH treatment. Next, we used human triple-negative breast cancer MDA-MB-468 cells, which expressed high levels of both Hec1 and Nek2, to test the efficacy of tumor growth in mouse xenograft. Once tumor volumes reached~100 mm 3 , mice were randomly divided into five treatment groups and began to receive thrice weekly intraperitoneal injections of vehicle control, 10 mg/kg INH41, 50 mg/kg INH41, 5 mg/kg INH154 or 20 mg/kg INH154. Treatment was continued for 6.5 weeks, and the tumor sizes were measured. Tumor growth rates in mice treated with INH41 or INH154 were evidently slower than those in control animals in a dose-dependent manner (Figures 6d and e ). Furthermore, 1 week after the last injections were administered, mice were killed and tumors were harvested for immunohistochemistry analysis. In agreement with the tumor growth data, the tumor proliferation index, determined by measuring BrdU (bromodeoxyuridine) staining, was clearly reduced in residual tumors treated with INH41 or INH154 in comparison with vehicle alone (Figure 6f ). The expression levels of Nek2 and Hec1 S165 phosphorylation were also substantially reduced in INH41-or INH154-treated tumors than in vehicle-treated tumors (Figures 6g and h) . Together, these results suggest that the new INH derivatives significantly suppress tumor growth in animals through the downregulation of Nek2 and abolishment of Hec1 S165 phosphorylation. On the other hand, body weights of the mice were measured during the 6.5 weeks treatment period and showed little difference among the treated and control groups (Supplementary Figure S9 ). In addition, we analyzed the toxicity of INHs by treating normal BALB/c ByJNarl mice with high dosage of INH41 (50 mg/kg) or INH154 (20 mg/kg) and showed no significant difference of body weights, blood chemistry and complete blood count analysis among these groups of animals ( Supplementary Table S3 ). These data suggested that INH treatment generates little or no toxicity.
DISCUSSION
The mitosis-specific roles of Hec1 and Nek2, and the poor clinical association of Hec1/Nek2 overexpression with human breast cancers, make the Hec1 and Nek2 interaction an ideal target for cancer therapy. In this communication, we demonstrated that the novel INH derivatives INH41 and INH154, which directly bind to Hec1, trigger degradation of Hec1-bound Nek2 at mitosis, impair Hec1 S165 phosphorylation and induce mitotic catastrophe and eventual cell death. Furthermore, we found that co-elevated expression of both Hec1 and Nek2 correlated with the shortest survival in breast cancer patients and treatment with INHs effectively ablates this kind of tumor growth in a xenograft model with little or no toxicity. Thus these compounds are suitable for translation into clinical application.
Compared with the first-generation compound INH1, our new lead compounds INH41 and INH154 are about 20-fold or 100-fold more potent, respectively. We have previously demonstrated that the isonicotinoyl and the thiazole moeities are both essential for INH activity. 26 The isonicotinoyl moeity is apparently involved in weak-to-moderate hydrogen bonds with E388 and Q392 (the distance between the pyridine nitrogen and E388 carboxyl oxygens is 4.0-4.3 Å; while the distance between the isonicotinoyl oxygen and Q392 nitrogen/oxygen atom is 3.2-4.6 Å). In addition to its hydrophobic nature, the indole side chain of W395 serves as a versatile π-donor 38 to electronically interact with the thiazole ring of INHs (the distance between the indole and thiazole rings in the INH154-Hec1 docking models is 3.0-3.7 Å). Guided by the docking model, more interaction points were secured to successfully increase the potency of this series of INH compounds. Particularly in INH154, the extended piperidine side chain apparently provides additional hydrophobic interactions with the side chains of residues L399 and K400. The distances between piperidine nitrogen of INH154 and the polar atoms of N396/K400/ R403 side chains are in the range of 5-7 Å in a rigid model. Considering possible side chain flexibility, the lone electron pair on this nitrogen of INH154 may serve as a hydrogen bond acceptor for donors from either one of the three Hec1 side chains. This is partly supported by the fact that amide analogues (INH146 and INH160) are generally less potent than amino/ether  analogues (INH57, INH79, INH81, INH130, INH154, INH158,  INH212 ). Further optimization based on the structure-activity relationship is certainly warranted.
Difficulties in defining clear-cut protein-protein interacting interface is one of the major challenges for drug design of this kind. 39 A successful example is probably p53/MDM2 disruptors, such as nutlins and RITA, following the unveiling of the p53-MDM2 crystal structures. [40] [41] [42] These compounds structurally mimic protein interfaces to disrupt the MDM2/p53 interaction, which in turn induce accumulation and reactivation of p53 in both cancer and normal cells. However, as all these compounds act through inhibiting MDM2 to restore p53 functions, they have limitation on cells with mutated or deleted p53. In the endeavor of seeking specific protein-protein interaction disruptors, we have taken a forward chemical genetic approach and identified RAD51 inactivator 43 and Hec1/Nek2 disruptors. 25 Interestingly, disruption of RAD51-BRC interaction and RAD51 multimerization by IBR2 triggers RAD51 degradation in cancer cells through proteasome pathway.
Intriguingly, INHs act through a completely different mechanism compared with either MDM2/p53 disruptors or IBR2. INHs directly bind Hec1 but induce degradation of Nek2. It is clear that this degradation is specific to Nek2, as neither Aurora A nor Plk1 was affected (Figure 4d and Supplementary Figure S3 ). We have shown previously that depletion of Hec1 by siRNA without drug treatment is not sufficient for Nek2 degradation 25 and expressing INH-binding-deficient Hec1 mutant in cells retarded INH-induced Nek2 degradation (Figure 5b and Supplementary Figure S6 ), suggesting that Nek2 degradation is specific for INH treatment. Importantly, the INH-induced Nek2 degradation requires direct interaction between Hec1 and Nek2. Expressing either Nek2binding-deficient Hec1 mutants or Hec1-binding-deficient Nek2 mutants renders resistance to Nek2 degradation in cancer cells upon INH treatment (Figures 5c-j) . The interaction between Hec1 and Nek2 occurs specifically at G2-M phase, 24 and INH treatment retarded G2/M progression, induced Nek2 degradation and activated apoptosis signal in cancer cells (Supplementary Figure  S10 ). However, INH treatment did not induce Nek2 degradation at G1/S phase (Supplementary Figure S11) . These findings indicate that targeting Hec1/Nek2 interaction by INHs triggered Nek2 degradation through specific temporal and spatial interaction between Hec1 and Nek2 at M phase.
How INH-Hec1 binding triggers Nek2 degradation is of interest. As the binding site of INHs to Hec1 is adjacent to Nek2-binding hot-spot site, it is likely that a distinct conformational change of Nek2 may take place when it binds to INH-bound Hec1 and signal for Nek2 degradation. Thus, INH-bound Hec1 interface may cooperatively serve as a 'death-trap' to entice Nek2 for degradation. Consistent to this notion, Nek2A D-box R361L mutant failed to bind Hec1 and appeared to be resistant to INH-induced degradation. The death-trap created by the interface of INHbound Hec1 may provide a unique mechanism rendering the targeted protein for proteasome degradation.
Elevated Hec1 or Nek2 levels have been detected in many types of aggressive tumors 34, [44] [45] [46] and correlated with poor prognosis as well as resistance to chemotherapy. 47 Consistently, we found that the high expression levels of both Hec1 and Nek2 strongly correlated with the shortest survivals based on the analysis of clinical breast cancer patient data (Figures 6a-c 
Cell lines and establishment of stable cell lines
Human breast cancer cell lines (MDA-MB-231 and MDA-MB-468), osteosarcoma line (U2OS), cervical adenocarcinoma line (HeLa) and normal skin fibroblast (Hs27) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The leukemia cell line (K562) and glioblastoma cell line (T98G) were grown in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin. Normal mammary epithelial cell line (MCF10A) was cultured in DMEM/F12 (50:50) supplemented with 5% horse serum, 0.1 μg/ml cholera toxin, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone and 20 ng/ml epidermal growth factor. To establish MDA-MB-468 cells that stably expressed each individual green fluorescent protein (GFP)-Hec1 constructs, cells were infected with respective retrovirus and were selected with 2 μg/ml puromycin.
Molecular docking
Receptor structure of Hec1 coiled-coil region was obtained by homology modeling using the ICM Pro (Molsoft L.L.C, San Diego, CA, USA), based on the crystal structure of the coiled-coil protein Tropomyosin (PDB Accession No: 1C1G, see Supplementary Methods and Supplementary Figure S1 ). Receptor pocket was identified using the automatic pocket finder of ICM Pro, and the largest pocket (Residues E375, Q378 -L418, R420, K431, L434, I435; volume = 2492 Å 3 ) was used for docking of small compounds. INHs structures were generated and optimized using the Molecular Editor in ICM Pro. 48 Interactive docking was performed using the ICM Pro, with the default setting (thoroughness = 1), and the docked conformations with lowest energy were chosen for further analysis.
Biotin INHs pull-down assay
Cells expressing GFP-Hec1 were lysed and subjected for sonication in Lysis 125 buffer. Cell extract was first preclarified with neutravidin-resin (Thermo Fisher Scientific Inc., Waltham, MA, USA) and then incubated with the neutravidin-resin conjugated with compound biotin for 3 h at 4°C. The resin was then collected and washed with 50 resin volumes washing buffer (Lysis 125 buffer with 0.15% trion-x-100). Finally, the proteins on resin were eluted with 2 × SDS (sodium dodecyl sulfate) loading buffer by boiling the resin for 10 min at 95°C heat plate. The supernatants were subjected to SDS-PAGE (polyacrylamide gel electrophoresis) and western blotting analysis.
Immunoprecipitation
Over 80% confluent cells in 10 cm Petri dish were lysed in 1 ml Lysis 125 buffer (50 mM Tris, pH 7.4, 125 mM NaCl, 5 mM EDTA, 5 mM ethylene glycol tetraacetic acis (EGTA), 0.1% Nonidet P-40, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), 500 nM Microcystin-LR and 1 × proteinase inhibitor cocktail (Roche, Indianapolis, IN, USA)) and subjected to three liquid nitrogen freeze-thaw cycles. Lysate was preclarified by incubating with Protein G Sepharose (pre-blocked with 5% bovine serum albumin/ phosphate-buffered saline for 2 h) for 1 h at 4°C. Clarified lysate was then removed from the beads and incubated with antibodies at 4°C for 2 h, followed by incubation of fresh Protein G Sepharose for 1 h at 4°C. Immunoprecipitates were washed three times with wash buffer (50 mM Tris, pH 7.4, 125 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 50 mM NaF and 1 mM PMSF). The lysates and immunoprecipitates were separated by SDS-PAGE and subjected to western blotting analysis.
Xenograft mice studies
All mice experiments were performed under the guidelines of the University of California at Irvine Animal Research Committee. Athymic nude mice (nu/nu; Harlan Sprague-Dawley Inc., Indianapolis, IN, USA) were maintained in pathogen-free conditions within the University Laboratory Animal Resources Center at the University of California according to the approved institutional protocols. MDA-MB-468 breast cancer cells (2 × 10 6 ) were injected into the mammary fat pads of 6-8-week-old nude mice. Once tumors reached~100 mm 3 , mice were divided into five treatment groups (n = 6 per group): vehicle control (5% DMSO, 7.5% ethanol, 7.5% Cremophor EL, 20% PEG400, 60% saline), 10 mg/kg INH41, 50 mg/kg INH41, 5 mg/kg INH154, or 20 mg/kg INH154. Mice were treated with vehicle control or INHs thrice weekly via intraperitoneal injection. Mice body weights and tumor sizes were measured twice weekly. Tumor volume was calculated as (length × width 2 )/2 (in mm), and data were presented as mean tumor volume ± s.e.m.
Statistical analyses
A two-tailed Student's t-test was used to assess tumor growth, immunostaining analysis, immunohistochemistry for pS165 Hec1, BrdU staining and IC 50 for INH41 or INH154 in MDA-MB-468 cells stably expressing GFP-Hec1 mutants. Single (*) and double asterisks (**) indicate Po0.05 and Po0.01, respectively.
All other experimental procedures are described in the Supplementary Materials and methods.
